Abstract

TP53 is a classic tumor suppressor, but its role in kidney cancer remains unclear. In our study, we tried to explain the role of p53 in kidney cancer through the p53-related enhancer RNA pathway. Functional experiments were used to explore whether P53-bound enhancer regions 2 (p53BER2) has a role in the cell cycle and senescence response of TP53-wild type (WT) renal cancer cells in vitro or vivo. RNA-sequencing was used to identify the potential target of p53BER2. The results showed that the expression level of P53BER2 was downregulated in renal cancer tissues and cell lines, further dual-luciferase experiments and APR-256-reactivated experiments showed p53BER2 expresses in a p53-dependent way. Moreover, knockdown p53BER2 could reverse nutlin-3-induced cytotoxic effect in TP53-WT cell lines. Further exploration showed the downregulation of p53BER2 could reverse nutlin-3-induced G1-arrest and senescence in TP53-WT cell lines. What is more, the knockdown of p53BER2 showed resistance to nutlin-3 treatment in vivo. Additionally, we found BRCA2 could be regulated by p53BER2 in vitro and vivo; further experiment showed p53BER2 could induce cell-cycle arrest and DNA repair by mediating BRCA2. In summary, the p53-associated enhancer RNA-p53BER2 mediates the cell cycle and senescence of p53 in TP53-WT renal cancer cells.

Details

Title
Cell-cycle arrest and senescence in TP53-wild type renal carcinoma by enhancer RNA-P53-bound enhancer regions 2 (p53BER2) in a p53-dependent pathway
Author
Xie Haibiao 1 ; Ma Kaifang 1 ; Zhang, Kenan 1 ; Zhou Jingcheng 1   VIAFID ORCID Logo  ; Li, Lei 1 ; Yang Wuping 1 ; Gong Yanqing 2 ; Cai, Lin 2 ; Gong Kan 1   VIAFID ORCID Logo 

 Peking University First Hospital, Department of Urology, Beijing, People’s Republic of China (GRID:grid.411472.5) (ISNI:0000 0004 1764 1621); Peking University, Institute of Urology, Beijing, People’s Republic of China (GRID:grid.11135.37) (ISNI:0000 0001 2256 9319); National Urological Cancer Center, Beijing, People’s Republic of China (GRID:grid.11135.37); Peking University First Hospital, Hereditary Kidney Cancer Research Center, Beijing, People’s Republic of China (GRID:grid.411472.5) (ISNI:0000 0004 1764 1621) 
 Peking University First Hospital, Department of Urology, Beijing, People’s Republic of China (GRID:grid.411472.5) (ISNI:0000 0004 1764 1621); Peking University, Institute of Urology, Beijing, People’s Republic of China (GRID:grid.11135.37) (ISNI:0000 0001 2256 9319); National Urological Cancer Center, Beijing, People’s Republic of China (GRID:grid.11135.37) 
Publication year
2021
Publication date
Jan 2021
Publisher
Springer Nature B.V.
e-ISSN
20414889
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2476047730
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.